Diagnosis and Management of Fatty Liver Disease

Initial Diagnostic Approach

The American Gastroenterological Association recommends screening high-risk populations for NAFLD, including patients with type 2 diabetes mellitus, metabolic syndrome, and overweight/obese patients (BMI >25 kg/m²) 1, 2
The American Association for the Study of Liver Diseases suggests that patients with incidental hepatic steatosis on imaging should undergo further evaluation for NAFLD 1, 3
The European Association for the Study of the Liver recommends obtaining a comprehensive metabolic panel, complete blood count with platelets, fasting glucose or hemoglobin A1c, fasting lipid profile, and INR as initial laboratory tests 3

The American College of Gastroenterology recommends using the FIB-4 index as the preferred initial test for fibrosis assessment, with a cutoff <1.3 (or <2.0 if age >65) to exclude advanced fibrosis 1, 4
The American Association for the Study of Liver Diseases suggests that patients with indeterminate FIB-4 scores (1.3-2.67) should undergo second-tier testing with transient elastography, MRE, or ELF panel 1, 4

The American Institute of Ultrasound in Medicine recommends using ultrasound as the most economical and widely available modality for detecting steatosis, although it has limited sensitivity for mild steatosis 5, 4
The European Association for the Study of the Liver suggests that MRI-PDFF is excellent for quantifying steatosis, but is primarily used in clinical trials 2, 4

The American Association for the Study of Liver Diseases recommends considering liver biopsy in patients with suspected NASH with advanced fibrosis, indeterminate noninvasive test results, or when concurrent chronic liver disease cannot be excluded 5, 6, 4

The American Gastroenterological Association recommends repeat testing in 2-3 years for patients with FIB-4 <1.3, as only 12% show significant progression in liver stiffness over 3 years 1

The American College of Gastroenterology warns against excluding NAFLD based on normal ALT alone, as half of NAFLD patients have normal transaminases 3
The European Association for the Study of the Liver cautions against assuming AST:ALT >1 excludes NAFLD, as this ratio reverses in advanced disease 3

The European Association for the Study of the Liver recommends calculating FIB-4 for all patients with suspected NAFLD or chronic liver disease, with a FIB-4 <1.3 indicating low risk, 1.3-2.67 indicating indeterminate zone requiring second-tier testing, and >2.67 indicating high risk, refer to hepatology 7
For indeterminate FIB-4, the American Association for the Study of Liver Diseases guidance identifies ELF panel as one of the commonly investigated noninvasive tools for advanced fibrosis 8

Meta-analysis of 11 studies (4,452 patients) showed ELF has AUROC 0.83 for detecting advanced fibrosis, with sensitivity >90% at low cut-off of 7.7 for excluding fibrosis, and specificity 0.86-0.90 for diagnosing advanced fibrosis at high cut-off of 9.8-10.18 7
The American Gastroenterological Association recommends ELF as a confirmatory prognostic test in lean NAFLD patients, with ELF scores ≥11.27 associated with significantly increased risk of hepatic decompensation and hepatocellular carcinoma 9

The European Association for the Study of the Liver 2021 guidelines specifically recommend ELF <9.8 to rule out advanced fibrosis, with a sensitivity of 80% and specificity of 90% for advanced fibrosis 7
The Korean Association for the Study of the Liver 2013 guidelines note ELF showed favorable results with AUROC 0.90, sensitivity 80%, and specificity 90% for advanced fibrosis 10

If ELF is unavailable or results are discordant with clinical suspicion, proceed directly to vibration-controlled transient elastography (VCTE/FibroScan) with cut-offs: <8 kPa rules out advanced fibrosis, ≥12 kPa suggests advanced fibrosis 7, 9
Consider MR elastography as the most accurate noninvasive method, though it is more expensive and suited for clinical trials rather than first-line use 7
Liver biopsy remains indicated when noninvasive tests are indeterminate, concurrent liver diseases cannot be excluded, or treatment decisions require histologic confirmation 8, 11